Restoring NK cell activity may contribute to the elimination of plasma cells from SLE patients, and elotuzumab (targeting SLAMF7) and daratumumab (targeting CD38) may contribute to the elimination of antibody producing cells in vitro [35]. Here, SLAMF7 is linked to systemic lupus erythematosus.